VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

TCT 2021 | Venetoclax and BEAM followed by ASCT for R/R NHL

Joseph Maakaron, MD, University of Minnesota, Minneapolis, MN, discusses the results of a Phase I dose-escalation study investigating venetoclax plus BEAM followed by autologous stem cell transplant (ASCT) for chemoresistant or high-risk relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). In this trial, venetoclax and BEAM demonstrated promising results as a safe and well-tolerated approach in a typical, elderly population. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter